As efforts to crack down on abortion increase around the U.S., contraceptives are bound to play an increasingly important role in family planning. But for many women, cost and access are still prohibitive factors. A cheaper, over-the-counter option could help close that gap while creating a sizable market for generic drugmaker Perrigo.
Advisers to the Food and Drug Administration earlier this week recommended that Perrigo’s oral contraceptive, called Opill, be made available without prescription. If the recommendation is adopted by the FDA, it would help widen access to birth control around the country.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Already a subscriber? Sign In